These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23390492)

  • 41. Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation.
    Cowling VH
    Oncogene; 2010 Feb; 29(6):930-6. PubMed ID: 19915615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
    Fribourg AF; Knudsen KE; Strobeck MW; Lindhorst CM; Knudsen ES
    Cell Growth Differ; 2000 Jul; 11(7):361-72. PubMed ID: 10939590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression.
    Qi Y; Tu Y; Yang D; Chen Q; Xiao J; Chen Y; Fu J; Xiao X; Zhou Z
    J Cell Physiol; 2007 Jan; 210(1):63-71. PubMed ID: 17013808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
    Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes.
    Ravanko K; Järvinen K; Paasinen-Sohns A; Hölttä E
    Cancer Res; 2000 Sep; 60(18):5244-53. PubMed ID: 11016654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways.
    Labalette C; Nouët Y; Levillayer F; Armengol C; Renard CA; Soubigou G; Xia T; Buendia MA; Wei Y
    PLoS One; 2008; 3(11):e3761. PubMed ID: 19018287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1.
    Xie Z; Zeng X; Waldman T; Glazer RI
    Cancer Res; 2003 Sep; 63(17):5370-5. PubMed ID: 14500370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cdk2: a key regulator of the senescence control function of Myc.
    Hydbring P; Larsson LG
    Aging (Albany NY); 2010 Apr; 2(4):244-50. PubMed ID: 20445224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1.
    Fezza M; Moussa M; Aoun R; Haber R; Hilal G
    PLoS One; 2019; 14(9):e0223252. PubMed ID: 31568519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
    Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
    Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mammary epithelial cell transformation: insights from cell culture and mouse models.
    Dimri G; Band H; Band V
    Breast Cancer Res; 2005; 7(4):171-9. PubMed ID: 15987472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation.
    Jackstadt R; Jung P; Hermeking H
    Cell Death Dis; 2013 Aug; 4(8):e775. PubMed ID: 23949224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
    Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
    BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
    Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
    Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
    Jang JW; Boxer RB; Chodosh LA
    Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M.
    Kan CE; Cipriano R; Jackson MW
    Cancer Res; 2011 Nov; 71(22):6930-9. PubMed ID: 21975934
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CDK2 is required by MYC to induce apoptosis.
    Deb-Basu D; Aleem E; Kaldis P; Felsher DW
    Cell Cycle; 2006 Jun; 5(12):1342-7. PubMed ID: 16760655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells.
    Motohara T; Masuko S; Ishimoto T; Yae T; Onishi N; Muraguchi T; Hirao A; Matsuzaki Y; Tashiro H; Katabuchi H; Saya H; Nagano O
    Carcinogenesis; 2011 Nov; 32(11):1597-606. PubMed ID: 21828057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.
    Inoue S; Hao Z; Elia AJ; Cescon D; Zhou L; Silvester J; Snow B; Harris IS; Sasaki M; Li WY; Itsumi M; Yamamoto K; Ueda T; Dominguez-Brauer C; Gorrini C; Chio II; Haight J; You-Ten A; McCracken S; Wakeham A; Ghazarian D; Penn LJ; Melino G; Mak TW
    Genes Dev; 2013 May; 27(10):1101-14. PubMed ID: 23699408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells.
    Fonti C; Saumet A; Abi-Khalil A; Orsetti B; Cleroux E; Bender A; Dumas M; Schmitt E; Colinge J; Jacot W; Weber M; Sardet C; du Manoir S; Theillet C
    Int J Cancer; 2019 Sep; 145(5):1299-1311. PubMed ID: 31093963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.